0001213900-26-046712
SEC filingIceCure Medical Ltd. is seeking shareholder approval for a potential reverse stock split of its ordinary shares at a ratio between 10:1 and 30:1, to be implemented at the Board’s discretion to support Nasdaq listing compliance and broaden investor appeal.
This filing announces a Special General Meeting of Shareholders to seek approval for a discretionary reverse stock split — a high-materiality corporate action directly impacting share structure, market perception, and exchange listing viability. The proposal grants the Board authority to implement a 10:1 to 30:1 reverse split at its sole discretion, contingent on Nasdaq compliance needs and market conditions. Crucially, the Company explicitly states it intends to request a 180-day additional compliance period under Nasdaq Listing Rule 5550(a)(2) to regain compliance with the $1.00 minimum bid price requirement — indicating current non-compliance or imminent risk thereof. Approval is not a commitment to execute the split, but rather a strategic contingency measure: the Board emphasizes flexibility to act decisively if required, avoiding delays that could jeopardize listing status. The reverse split would affect all equity securities uniformly — including options, RSUs, and warrants — preserving proportional ownership and voting rights, while eliminating fractional shares via rounding. Broker non-votes are expected for beneficial owners who fail to provide voting instructions, as the proposal is deemed non-routine under Nasdaq rules. Given the direct linkage to continued Nasdaq listing — a critical enabler of public capital access and liquidity — and the absence of alternative remediation plans disclosed, this vote represents a pivotal governance and financial stability milestone for investors.